Integrated experimental and network pharmacology evaluation of a defined phytochemical combination in diabetes-related models

Aim This study evaluated a predefined combination of curcumin, quercetin, forskolin, and gymnemic acid using both experimental and computational approaches. Methods The phytochemical combination of curcumin, quercetin, forskolin, gymnemic acid was assessed through diabetes-related enzyme inhibition and free radical scavenging assays. Acute and 90-day oral toxicity studies were conducted to evaluate safety. Two independent cohorts of rats induced with streptozotocin one over 120 days and the other over 90 day- were used to examine outcomes related to glycaemia, biochemistry, oxidative stress, inflammation, histology, and pancreatic insulin-immunoreactivity outcomes. Network pharmacology and molecular docking methods were employed to generate mechanistic hypotheses. Results PCC inhibited the activities of α-amylase, α-glucosidase, DPP-IV, and aldose reductase. Inhibition of glucose-6-phosphatase, PTP1B, cholesterol esterase, and pancreatic lipase was minimal or undetected. PCC demonstrated scavenging activity against DPPH and ABTS radicals. No consistent treatment-related toxicity was observed during the 90 days of dosing at doses up to 600 mg/kg/day, the highest tested. Both streptozotocin cohorts showed that PCC improved glycaemia and some selected metabolic and oxidative stress measures, as well as pancreatic insulin immunoreactivity and inflammatory markers; however, these findings do not indicate β-cell regeneration or a mechanism for type 2 diabetes. Network and docking analyses generated only predicted associations. Conclusion The predefined PCC exhibited selective inhibition of diabetes-related enzymes, demonstrated free radical scavenging activity, and showed preliminary effects in vivo . The computational findings are exploratory but hypothesis-generating and require pharmacokinetic and molecular validation. Neither synergy nor direct engagement of the predicted molecular targets was established.

Authors

Institutions

Publication Details

Journal
Biomedicine & Pharmacotherapy
Published
2026-10-07
DOI
https://doi.org/10.1016/j.biopha.2026.119966
Primary Topic
Natural Antidiabetic Agents Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Integrated experimental and network pharmacology evaluation of a defined phytochemical combination in diabetes-related models

Vadlapudi Kumar, Poorna Vivek Valleti, D.V. Poornima, H.L. Raghavendra et al.
Biomedicine & Pharmacotherapy
Natural Antidiabetic Agents Studies
article

Integrated experimental and network pharmacology evaluation of a defined phytochemical combination in diabetes-related models

Vadlapudi Kumar, Poorna Vivek Valleti, D.V. Poornima, H.L. Raghavendra, T. Manjunatha
article en

Abstract

Aim This study evaluated a predefined combination of curcumin, quercetin, forskolin, and gymnemic acid using both experimental and computational approaches. Methods The phytochemical combination of curcumin, quercetin, forskolin, gymnemic acid was assessed through diabetes-related enzyme inhibition and free radical scavenging assays. Acute and 90-day oral toxicity studies were conducted to evaluate safety. Two independent cohorts of rats induced with streptozotocin one over 120 days and the other over 90 day- were used to examine outcomes related to glycaemia, biochemistry, oxidative stress, inflammation, histology, and pancreatic insulin-immunoreactivity outcomes. Network pharmacology and molecular docking methods were employed to generate mechanistic hypotheses. Results PCC inhibited the activities of α-amylase, α-glucosidase, DPP-IV, and aldose reductase. Inhibition of glucose-6-phosphatase, PTP1B, cholesterol esterase, and pancreatic lipase was minimal or undetected. PCC demonstrated scavenging activity against DPPH and ABTS radicals. No consistent treatment-related toxicity was observed during the 90 days of dosing at doses up to 600 mg/kg/day, the highest tested. Both streptozotocin cohorts showed that PCC improved glycaemia and some selected metabolic and oxidative stress measures, as well as pancreatic insulin immunoreactivity and inflammatory markers; however, these findings do not indicate β-cell regeneration or a mechanism for type 2 diabetes. Network and docking analyses generated only predicted associations. Conclusion The predefined PCC exhibited selective inhibition of diabetes-related enzymes, demonstrated free radical scavenging activity, and showed preliminary effects in vivo . The computational findings are exploratory but hypothesis-generating and require pharmacokinetic and molecular validation. Neither synergy nor direct engagement of the predicted molecular targets was established.

Biomedicine & PharmacotherapyVol. 204
University B.D.T College of Engineering (IN), Kuvempu University (IN), Davangere University (IN)
Openalex Percentile: Top 11%
Natural Antidiabetic Agents Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.